Equities Analysts Issue Forecasts for RYTM Q2 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Rhythm Pharmaceuticals in a report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.40) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals' Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.18) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). The company had revenue of $41.83 million for the quarter, compared to analyst estimates of $38.48 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%.

RYTM has been the subject of a number of other research reports. The Goldman Sachs Group lifted their price objective on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a "buy" rating in a research note on Thursday, December 5th. Morgan Stanley reiterated an "overweight" rating and set a $72.00 price target on shares of Rhythm Pharmaceuticals in a research report on Friday, March 7th. Needham & Company LLC upped their price objective on Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, March 18th. Jefferies Financial Group started coverage on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They set a "buy" rating and a $80.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They issued a "buy" rating and a $78.00 target price for the company. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $69.46.

Remove Ads

Rhythm Pharmaceuticals Price Performance

Rhythm Pharmaceuticals stock traded up $1.31 during trading hours on Tuesday, hitting $54.80. 416,136 shares of the stock traded hands, compared to its average volume of 509,820. The firm's 50 day moving average price is $55.25 and its 200-day moving average price is $55.07. The stock has a market capitalization of $3.46 billion, a price-to-earnings ratio of -12.66 and a beta of 2.30. Rhythm Pharmaceuticals has a 1 year low of $35.17 and a 1 year high of $68.58.

Insiders Place Their Bets

In related news, insider Joseph Shulman sold 1,281 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $76,129.83. Following the completion of the transaction, the insider now directly owns 2,657 shares in the company, valued at approximately $157,905.51. This represents a 32.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Yann Mazabraud sold 75,000 shares of Rhythm Pharmaceuticals stock in a transaction on Friday, March 14th. The shares were sold at an average price of $51.48, for a total value of $3,861,000.00. Following the completion of the sale, the executive vice president now owns 40,370 shares in the company, valued at $2,078,247.60. This represents a 65.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 108,131 shares of company stock valued at $5,781,098 over the last ninety days. Company insiders own 5.60% of the company's stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

A number of hedge funds have recently modified their holdings of RYTM. SRS Capital Advisors Inc. raised its holdings in Rhythm Pharmaceuticals by 740.7% in the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock valued at $25,000 after buying an additional 400 shares during the period. Raleigh Capital Management Inc. acquired a new stake in shares of Rhythm Pharmaceuticals during the fourth quarter valued at about $28,000. SBI Securities Co. Ltd. purchased a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter valued at approximately $37,000. R Squared Ltd purchased a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter valued at approximately $44,000. Finally, State of Wyoming acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth approximately $61,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.